Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Create Market That Encourages Innovation: Mr Iwai of OPIR
January 19, 2009
- Give Patents to New Therapeutic Methods
January 19, 2009
- BUSINESS NEWS IN BRIEF
January 19, 2009
- Data on Tamiflu Should Be Published: Medwatcher Japan
January 19, 2009
- Sanjou General Hospital to Switch to In-House Prescriptions
January 19, 2009
- Council Chairman Proposes Reform of Vaccine Administration
January 19, 2009
- REGULATORY NEWS IN BRIEF
January 19, 2009
- SymBio Begins PI Trial of Bendamustine for New Indication
January 19, 2009
- Merger of Mediceo Paltac, Alfresa Aborted
January 19, 2009
- R&D NEWS IN BRIEF
January 19, 2009
- CMIC Aims at Launching Human Hemin in 2011
January 19, 2009
- J-TEC's Jace Becomes Available under Health Insurance
January 19, 2009
- JPMA to Place Top Priority on NHI Drug Pricing System Reform in 2009: Mr Shoda
January 19, 2009
- MHIR Develops Software to Predict Secondary RNA Structures
January 19, 2009
- Bayer Schering Licenses PET Tracers from Hamamatsu Photonics
January 19, 2009
- Korosho to Talk with NCVC on Evaheart Issue
January 19, 2009
- Sales of Generics Top ¥10 Bil. at Meiji Seika
January 19, 2009
- Team of 16 Organizations Aims at Developing Artificial Joints Durable for 30 Years
January 19, 2009
- Kyowa Kirin to Transfer Neu-Up to Avoid Problems with AML
January 12, 2009
- Korosho to Educate Doctors on Benefits of Generics
January 12, 2009
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…